![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics to Present at the ROTH 23rd Annual OC Growth Stock Conference on Tuesday, March 15, 2011
10 mars 2011 07h00 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., March 10, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the ROTH 23rd Annual OC Growth Stock Conference at 9:00 AM PT on...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics Reports Fourth Quarter and Full Year 2010 Results
02 mars 2011 16h15 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., March 2, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the fourth quarter and full year 2010 and will host a...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2010 Results
25 févr. 2011 07h30 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Feb. 25, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release fourth quarter and full year 2010 results after the market...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics Completes Public Offering of Common Stock
24 févr. 2011 16h15 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Feb. 24, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has completed its previously announced public offering of common stock and announced that the...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics Prices Public Offering of Common Stock
18 févr. 2011 08h00 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Feb. 18, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today that it has priced a public offering of 8.75 million shares of its common...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics Announces Public Offering of Common Stock
17 févr. 2011 16h04 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Feb. 17, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today its intention, subject to market and other conditions, to offer $35 million in...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics to Present at 13th Annual BIO CEO & Investor Conference
14 févr. 2011 08h00 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Feb. 14, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 13th Annual BIO CEO & Investor Conference at 1:30 PM ET on...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics Announces Interim Results and Plans to Modify Study 306 to Focus on Reduction in Falls Associated With Neurogenic Orthostatic Hypotension
02 févr. 2011 07h00 HE
|
Chelsea Therapeutics
Independent Data Monitoring Committee Concludes Continuation of Study Using Subjective OHQ Composite Endpoint Futile While Unblinded Analysis Reveals Robust Efficacy Reflected in Objective Falls...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics Reports Data Demonstrating Sustained Symptomatic Benefit of Northera in Neurogenic Orthostatic Hypotension Over 12-Month Treatment Period
20 janv. 2011 07h00 HE
|
Chelsea Therapeutics
Patients Continue to Report Statistically Significant 2.8 Unit Improvement in OHQ Composite Scores Following 12 Months of Open Label Treatment With Northera (p<0.001)
Parkinson's Disease...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics Accelerates Northera NDA Filing Following Meeting With FDA
20 déc. 2010 06h30 HE
|
Chelsea Therapeutics
Chelsea to File for US Marketing Approval of Northera in Symptomatic Neurogenic Orthostatic Hypotension in Q2 2011 Based on Efficacy Data from Phase III Studies 301 and 302
FDA Will Not...